AC Immune (ACIU) grants RSUs and stock options to director Buetler

Rhea-AI Filing Summary

AC Immune SA director Monika Buetler received new equity awards as part of her compensation. On June 11, 2026, she was granted 17,751 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan. The grant increases her direct interest in the company without any cash purchase.

On the same date, she also received share options for 41,667 common shares at an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. After these awards, she directly holds 71,656 common shares, largely reflecting restricted share units rather than open-market buying.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Buetler Monika

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	41,667	$0.00	--
Grant/Award	Common Share	17,751	$0.00	--

Holdings After Transaction: Share Option (right to buy) — 41,667 shares (Direct, null); Common Share — 71,656 shares (Direct, null)

Footnotes (1)

1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 17,751 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). Includes 70,656 common shares underlying outstanding restricted share units. On June 11, 2026, the Reporting Person received share options with respect to 41,667 shares under the SOIP. The share options will fully vest on June 10, 2027.

Key Figures

RSU grant: 17,751 units Option grant size: 41,667 options Option exercise price: $2.62 per share +3 more

6 metrics

RSU grant 17,751 units Restricted share units granted on June 11, 2026

Option grant size 41,667 options Share options granted on June 11, 2026

Option exercise price $2.62 per share Exercise price for 41,667 share options

Option vesting date June 10, 2027 Date options fully vest

Option expiration date June 10, 2036 Expiration for granted share options

Shares held after grants 71,656 shares Total common shares directly held following transactions

Key Terms

restricted share unit, AC Immune SA 2016 Stock Option and Incentive Plan, share options, vest

4 terms

restricted share unit financial

"the Reporting Person received a restricted share unit grant of 17,751 units"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

AC Immune SA 2016 Stock Option and Incentive Plan financial

"grant of 17,751 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP)"

share options financial

"the Reporting Person received share options with respect to 41,667 shares under the SOIP"

Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.

vest financial

"The share options will fully vest on June 10, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buetler Monika

(Last) (First) (Middle)

BACHTOBELSTRASSE 44

(Street)

ZURICH 8045

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Share	06/11/2026		A		17,751	A	$0(1)	71,656(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.62	06/11/2026		A		41,667		06/10/2027(3)	06/10/2036	Common Share	41,667	$0	41,667	D

Explanation of Responses:

1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 17,751 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).

2. Includes 70,656 common shares underlying outstanding restricted share units.

3. On June 11, 2026, the Reporting Person received share options with respect to 41,667 shares under the SOIP. The share options will fully vest on June 10, 2027.

	Matthias Maurer as Attorney-in-Fact for Monika Buetler	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AC Immune (ACIU) director Monika Buetler receive in this Form 4?

Director Monika Buetler received equity-based compensation, not cash. She was granted 17,751 restricted share units and share options on 41,667 common shares, reflecting standard incentive awards rather than open-market share purchases or sales.

How many AC Immune (ACIU) restricted share units were granted to Monika Buetler?

Monika Buetler received 17,751 restricted share units. These units were granted under AC Immune SA’s 2016 Stock Option and Incentive Plan and represent a right to receive common shares in the future, typically subject to vesting conditions.

What are the key terms of Monika Buetler’s new AC Immune (ACIU) share options?

She received options over 41,667 common shares at an exercise price of $2.62 per share. The options fully vest on June 10, 2027 and expire on June 10, 2036, giving a long-term window to exercise.

Did Monika Buetler buy or sell AC Immune (ACIU) shares on the market?

No open-market buying or selling is reported. The Form 4 shows grant or award acquisitions only, consisting of restricted share units and stock options provided as compensation, with no indicated purchase or sale at market prices.

How many AC Immune (ACIU) shares does Monika Buetler hold after these awards?

After the June 11, 2026 grants, she directly holds 71,656 common shares. Footnotes indicate this figure includes a substantial number of shares underlying outstanding restricted share units rather than solely previously owned stock.

Under which plan were Monika Buetler’s AC Immune (ACIU) awards granted?

Both the 17,751 restricted share units and the 41,667 share options were granted under the AC Immune SA 2016 Stock Option and Incentive Plan, which governs the company’s equity-based compensation for eligible participants.